TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25222630
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation and multi-family group treatment (CR-MFG)
Study: 20797407
Drug: Intravenous micafungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous micafungin (MCFG) 150-300 mg once daily
Study: 20797407
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole (VRCZ) 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily
Study: 11867369
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol (150‐mg bolus followed by infusion, total 450 mg/24 h)
Study: 11867369
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg, then 0.2 mg/h)
Study: 7593870
Drug: Individualized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized cognitive treatment (CT)
Study: 1958108
Drug: ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivermectin 100 mcg/kg
Study: 1796228
Drug: DEC 3
Normalized name: Zodryl DEC 35 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 3 mg/kg
Study: 1958108
Drug: ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivermectin 100 mcg/kg or DEC 3 mg/kg (2 successive doses)
Study: 1958108
Drug: ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivermectin 100 mcg/kg or DEC 3 mg/kg
Study: 6211296
Drug: sulfinpyrazone, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfinpyrazone, 800 mg/day
Study: 22157240
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) taken daily for 8 weeks
Study: 16036193
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of a mixture of 10 mL of 0.5% bupivacaine (50 mg) with epinephrine (1:500) in 40 mL of Ringer's lactate solution postoperatively (Group A)
Study: 16036193
Drug: The same
Normalized name: This Is The Same Medication Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same mixture solution infusion preoperatively and postoperatively (total 100 mg bupivacaine) (Group B)
Study: 10825867
Drug: Opalescence (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opalescence (10% carbamide peroxide gel)
Study: 10825867
Drug: NiteWhite Excel
Normalized name: chlorhexidine diacetate Topical Ointment [Excel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NiteWhite Excel (10% carbamide peroxide gel)
Study: 7578781
Drug: Fixed bridge
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed bridge between the distal tooth of the residual dentition and an implant
Study: 7578781
Drug: Free-standing bridge
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-standing bridge on 2 implants
Study: 7578781
Drug: Implant-supported bridges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported bridges
Study: 7578781
Drug: Tooth-implant fixed
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-implant fixed bridges
Study: 2154154
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer (1.75 ml, 1,750 micrograms of radiolabeled fenoterol solution)
Study: 6814282
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with two timothy major allergens, 19, 25, or partially purified timothy extract
Study: 31438986
Drug: Tocilizumab 12
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 12 mg/kg IV every 2 weeks (Q2W)
Study: 1961665
Drug: Caffeine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2.5 mg/kg
Study: 1961665
Drug: Caffeine 5.0
Normalized name: CAFFEINE 5.0 mg in 1000 mL TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5.0 mg/kg
Study: 23720124
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection with local corticosteroids
Study: 21540198
Drug: Canakinumab 100
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 100 mg
Study: 21540198
Drug: Canakinumab 200
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 200 mg
Study: 21540198
Drug: Canakinumab (50+50+25+25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50+50+25+25 mg)
Study: 2606428
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg
Study: 22507493
Drug: Low-dose abdominal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose abdominal computed tomography (LDCT)
Study: 15205246
Drug: Brimonidine purite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine purite 0.15% given twice daily
Study: 15205246
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% given twice daily
Study: 11087239
Drug: Doxazosin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin administration (subgroup 1B, n = 7)
Study: 11087239
Drug: No doxazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No doxazosin administration (subgroup 1A, n = 7)
Study: 8922160
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion for 12 to 18 hours after intervention
Study: 8922160
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin infusion
Study: 1343613
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg b.i.d. lovastatin (Mevacor)
Study: 31144304
Drug: PPARÎ´ agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARÎ´ agonist GW501516
Study: 31144304
Drug: PPARÎ´ antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARÎ´ antagonist GSK0660
Study: 23060037
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg daily)
Study: 17465970
Drug: Naproxen 10
Normalized name: naproxen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 10 mg/kg
Study: 17465970
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg/kg i.v.
Study: 17465970
Drug: Naproxen, Paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, Paracetamol, and Placebo with Pethidine
Study: 11257737
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (n = 24)
Study: 11257737
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of antibiotics (n = 35)
Study: 11257737
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of antibiotics (n = 31)
Study: 31998285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving antibiotics)
Study: 9439944
Drug: Valproate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (1 g per day) for 8 weeks
Study: 9439944
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg per day) for 8 weeks
Study: 2827920
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (1% nasal spray)
Study: 28803502
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg recombinant hepatitis B vaccine
Study: 28803502
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg recombinant hepatitis B vaccine
Study: 23452187
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy
Study: 9311953
Drug: Control cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cereal (≤3 g soluble fiber/d)
Study: 2859185
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg thrice daily
Study: 2859185
Drug: Felodipine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 7.5 mg twice daily
Study: 24717369
Drug: Raised C-reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raised C-reactive protein (CRP; >5 mg/L)
Study: 24717369
Drug: Modified relative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified relative dose response values
Study: 14709290
Drug: topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical betaxolol 0.5% solution
Study: 10870778
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral azithromycin 1 g
Study: 10870778
Drug: Seven-day doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seven-day doxycycline 100 mg twice daily
Study: 9586517
Drug: Real Low-Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real Low-Level Laser therapy (830 nm Ga‐Al‐As Laser, 4 joules, 3 sessions)
Study: 9586517
Drug: Real Low-Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real Low-Level Laser therapy
Study: 8436152
Drug: Zabicipril 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabicipril 0.5 mg, 1 mg, or 2.5 mg
Study: 3464039
Drug: Ibuprofen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (single dose)
Study: 29908319
Drug: Free vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free vitamin D3 concentrations < 5pg/mL
Study: 29908319
Drug: Free vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free vitamin D3 concentrations 5 to 9pg/mL
Study: 29908319
Drug: Free vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free vitamin D3 concentrations > 9pg/mL
Study: 19941048
Drug: Telephone‐administered Cognitive‐Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone‐administered Cognitive‐Behavioral Therapy (T‐CBT)
Study: 19941048
Drug: Telephone‐administered Emotion‐Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone‐administered Emotion‐Focused Therapy (T‐EFT)
Study: 10086671
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM)
Study: 10086671
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM) plus compliance enhancing measures
Study: 1896092
Drug: 1 alpha-OH-D3
Normalized name: 1-alpha-25-Dihydroxyvitamin D3
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 alpha-OH-D3 and calcium carbonate (existing treatment)
Study: 6367434
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg four times a day
Study: 24755124
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet with food
Study: 24755124
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet without food
Study: 24755124
Drug: FDC tablets
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablets with normal dissolution characteristics
Study: 24755124
Drug: FDC tablets
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablets with slower dissolution characteristics
Study: 23711168
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for pain and insomnia (CBT-PI)
Study: 25365778
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for pain (CBT-P)
Study: 20211222
Drug: Anti-cholinergic bronchodilator
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cholinergic bronchodilator (ipratropium bromide)
Study: 16633103
Drug: Mesalazine 1.6
Normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 1.6 g/d
Study: 16633103
Drug: Mesalazine 1.6
Normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 1.6 g/d + Lactobacillus casei DG 16 billion/d for 15 d/mo
Study: 8930427
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (granules from a 30‐mg capsule mixed with apple juice and administered through a nasogastric tube)
Study: 7585848
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (an intact 30‐mg capsule)
Study: 1528957
Drug: Imipramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine plus Mianserin (30 mg daily)
Study: 3987221
Drug: Controlled-release pseudoephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release pseudoephedrine formulations
Study: 3987221
Drug: Optimal controlled-release
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal controlled-release formulation from single-dose study
Study: 3987221
Drug: Immediate-release pseudoephedrine
Normalized name: pseudoephedrine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release pseudoephedrine hydrochloride
Study: 3987221
Drug: Reference pseudoephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference pseudoephedrine hydrochloride syrup
Study: 25877234
Drug: Bur preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bur preparation
Study: 25877234
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods (Er:YAG laser and Bur preparation)
Study: 8618434
Drug: Fludarabine- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine- and high-dose cytarabine-containing regimens
Study: 6434367
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of LactAid added to milk
Study: 29902286
Drug: Sequential strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential strategy (letrozole followed by tamoxifen)
Study: 23442547
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (compensating extraction of the upper first permanent molar)
Study: 21042881
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (1.0 g/kg)
Study: 21042881
Drug: 23.4% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.4% saline (0.686 mL/kg)
Study: 16608860
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy during ICU stay
Study: 16608860
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy during ICU stay (with at least 3 days of insulin therapy)
Study: 2542427
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) therapy
Study: 1914373
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral nifedipine
Study: 1290431
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous hydralazine
Study: 6746322
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (10,000 micrograms/d) for 4 weeks
Study: 15577414
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine gel
Study: 19571802
Drug: Atorvastatin (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (34 ± 26 mg/day)
Study: 19571802
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of atorvastatin
Study: 9133199
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository 100 mg
Study: 9133199
Drug: Ketorolac IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac IM injection 30 mg
Study: 2251987
Drug: Urokinase 2
Normalized name: UROKINASE 250000UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 2 million units as an intravenous bolus before hospital admission (group A)
Study: 2251987
Drug: Urokinase 2
Normalized name: UROKINASE 250000UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 2 million units as an intravenous bolus after hospital admission (group B)
Study: 26715771
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (5% of P(Imax)) for 6 weeks
Study: 23545807
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 2.5 g
Study: 23545807
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 5 g
Study: 23545807
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 10 g
Study: 21753726
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of xenon
Study: 9316325
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative analgesia of intravenous (i.v.) meperidine HCl (Demerol)
Study: 9316325
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia using epidural infusion of local anesthetics plus ketamine and morphine during surgery, and intermittent epidural morphine infusion for postoperative pain control when necessary, along with i.v. Demerol as in Group A
Study: 3567016
Drug: Promethazine 20
Normalized name: promethazine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 20 mg
Study: 3567016
Drug: Promethazine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 40 mg
Study: 31571349
Drug: Combined IVIg
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IVIg (2g/kg loading dose, 1g/kg maintenance every 3 weeks) and IVMP (1g every 3 weeks for 18 weeks); cumulative steroid dose 7g
Study: 31331390
Drug: Atrophic gastritis
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atrophic gastritis (PGI < 30 μg/L or PGI: PGII < 3.0)
Study: 30514858
Drug: CagA antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CagA antibody positive
Study: 22681259
Drug: Capsaicin 0.1%
Normalized name: CAPSAICIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 0.1% hydrogel patch
Study: 22681259
Drug: Control hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hydrogel patch without capsaicin
Study: 20493191
Drug: Higher fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher fat (HF) cream cheese
Study: 20493191
Drug: Lower fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower fat (LF) cream cheese
Study: 17568412
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg i.v. glucose
Study: 15743346
Drug: On medications
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On medications for heartburn
Study: 15743346
Drug: Off medications
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off medications for 1 week while symptomatic
Study: 15743346
Drug: On and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: On and off antireflux medications
Study: 15743346
Drug: Off medications
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off medications for patients with comorbid conditions
Study: 12036207
Drug: Thermal water
Normalized name: thermal water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal water from Cserkeszölö (active treatment)
Study: 12036207
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (placebo treatment)
Study: 9951980
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer measles vaccine
Study: 9951980
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer measles vaccine with rash
Study: 9951980
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer measles vaccine without rash
Study: 1824203
Drug: Lovastatin (L)
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin (L)
Study: 29081160
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg loading dose and 10 mg·kg(‐1)·h(‐1) infusion dose)
Study: 25143294
Drug: VLNC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLNC + PLA (very low nicotine content cigarettes with placebo patches)
Study: 25143294
Drug: VLNC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLNC + NIC (very low nicotine content cigarettes with nicotine patches totaling 42mg)
Study: 21324825
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine 3 times daily